Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OptiMATe: De-escalated Induction Treatment in Newly Diagnosed PCNSL
NCT04931368Phase 3Active, not recruiting
- Sponsor
- Klinikum Stuttgart
- Start
- Jun 2021
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab, methotrexate, cytarabine and thiotepa in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Klinikum Stuttgart. Primary endpoint: Event-free survival. Started Jun 2021; status: active, not recruiting.
02
Drugs
rituximabmethotrexatecytarabinethiotepa
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT04931368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04931368.